A patient has been taking donepezil for 2 weeks as part of the treatment for early stages of Alzheimer's disease. Her daughter calls the prescriber's office and is upset because "Mother has not improved one bit!" Which response by the nurse is appropriate?

A. Improved ability to perform activities of daily living: Antiparkinson medications are aimed at improving motor symptoms such as tremors, rigidity, and bradykinesia, leading to improved function in activities of daily living.
B. Decreased appetite: Decreased appetite is not a therapeutic response to antiparkinson medications. In fact, some medications may cause weight gain due to increased appetite.
C. Newly developed dyskinesias: Dyskinesias are involuntary movements that can occur as a side effect of long-term treatment with antiparkinson medications, particularly levodopa. They are not a therapeutic response and may require adjustments to medication.
D. Gradual development of cogwheel rigidity: Cogwheel rigidity is a symptom of Parkinson's disease and would not be expected to develop gradually with treatment. Antiparkinson
medications aim to reduce rigidity, not cause it.

A. Diarrhea is not typically associated with ergotamine toxicity. Gastrointestinal symptoms such as nausea and vomiting are more common adverse effects of ergotamine use.
B. Delirium is a potential sign of ergotamine toxicity. At toxic levels, ergotamine can cause central nervous system symptoms such as confusion, hallucinations, and delirium.
C. Hypotension may occur as an adverse effect of ergotamine due to its vasoconstrictive properties. However, hypotension alone may not indicate ergotamine toxicity.
D. Bradycardia is not a typical adverse effect of ergotamine. Ergotamine is more commonly associated with vasoconstriction and can lead to hypertension or tachycardia rather than bradycardia.

A. Diarrhea is not typically associated with ergotamine toxicity. Gastrointestinal symptoms such as nausea and vomiting are more common adverse effects of ergotamine use.
B. Delirium is a potential sign of ergotamine toxicity. At toxic levels, ergotamine can cause central nervous system symptoms such as confusion, hallucinations, and delirium.
C. Hypotension may occur as an adverse effect of ergotamine due to its vasoconstrictive properties. However, hypotension alone may not indicate ergotamine toxicity.
D. Bradycardia is not a typical adverse effect of ergotamine. Ergotamine is more commonly associated with vasoconstriction and can lead to hypertension or tachycardia rather than bradycardia.